| Literature DB >> 27891531 |
Andrea Dos Santos Dantas1, Luiz Carlos Klein-Júnior2, Miriana S Machado3, Temenouga N Guecheva3, Luciana D Dos Santos1, Régis A Zanette4, Fernanda B de Mello5, João Antonio Pêgas Henriques3, João Roberto Braga de Mello6.
Abstract
The present study aimed to investigate the in vitro mutagenic activity of Origanum majorana essential oil. The most abundant compounds identified by GC-MS were γ-terpinene (25.73%), α-terpinene (17.35%), terpinen-4-ol (17.24%), and sabinene (10.8%). Mutagenicity was evaluated by the Salmonella/microsome test using the preincubation procedure on TA98, TA97a, TA100, TA102, and TA1535 Salmonella typhimurium strains, in the absence or in the presence of metabolic activation. Cytotoxicity was detected at concentrations higher than 0.04 μL/plate in the absence of S9 mix and higher than 0.08 μL/plate in the presence of S9 mix and no gene mutation increase was observed. For the in vitro mammalian cell micronucleus test, V79 Chinese hamster lung fibroblasts were used. Cytotoxicity was only observed at concentrations higher than or equal to 0.05 μg/mL. Moreover, when tested in noncytotoxic concentrations, O. majorana essential oil was not able to induce chromosome mutation. The results from this study therefore suggest that O. majorana essential oil is not mutagenic at the concentrations tested in the Salmonella/microsome and micronucleus assays.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27891531 PMCID: PMC5116495 DOI: 10.1155/2016/3694901
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Chemical composition of the Origanum majorana essential oil.
| Compound | RIa | % |
|---|---|---|
|
| 921 | 3.96 |
|
| 927 | 1.24 |
| Sabinene | 966 | 10.80 |
| Myrcene | 986 | 2.08 |
|
| 1000 | 1.70 |
|
| 1012 | 17.35 |
|
| 1019 | 2.24 |
|
| 1023 | 7.05 |
|
| 1053 | 25.73 |
| Terpinolene | 1082 | 3.76 |
| N.I.b | 1097 | 1.06 |
| Terpinen-4-ol | 1174 | 17.24 |
|
| 1248 | 0.13 |
| Linalool acetate | 1251 | 1.38 |
| Terpinenen-4-ol acetate | 1293 | 0.88 |
|
| 1404 | 2.72 |
| N.I.b | 1480 | 0.67 |
| Total identified | 98.26 |
aRelative retention index experimentally determined against n-alkanes on Durabond-DB5 column. bCompound not identified.
Range finding study of the O. majorana essential oil using the TA100 strain.
| Substance | Concentration | Without metabolic activation (−S9) | With metabolic activation (+S9) | ||
|---|---|---|---|---|---|
| Rev/platea | MIb | Rev/platea | MIb | ||
| NCa | — | 141.33 ± 17.56 | — | 148.00 ± 4.58 | — |
| Essential oil | 0.008 | 105.67 ± 22.01 | 0.75 | 145.33 ± 18.15 | 0.98 |
| 0.04 | 53.00 ± 9.64 | 0.38b | 127.00 ± 19.47 | 0.86 | |
| 0.2 | 33.00 ± 23.07 | 0.23b | 72.67 ± 13.05 | 0.49b | |
| 1 | 0.33 ± 0.58 | 0.00 | 0.33 ± 0.58 | 0.00 | |
| 5 | 0.00 ± 0.00 | 0.00 | 0.00 ± 0.00 | 0.00 | |
aNegative control: DMSO (10 µL). bCytotoxicity.
Induction of his+ revertants in S. typhimurium strains by Origanum majorana essential oil with and without metabolic activation (S9 mix).
| Substance | Concentration |
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TA98 | TA97a | TA100 | TA1535 | TA102 | |||||||
| Rev/platea | MIb | Rev/platea | MIb | Rev/platea | MIb | Rev/platea | MIb | Rev/platea | MIb | ||
| Without metabolic activation (−S9) | |||||||||||
| NCc | — | 19.7 ± 8.2 | — | 69.7 ± 3.1 | — | 103.7 ± 6.1 | — | 4.3 ± 2.5 | — | 291.7 ± 10.5 | — |
| Essential oil | 0.0025 | 24.7 ± 6.4 | 1.03 | 91.7 ± 7.5 | 1.32 | 102.3 ± 9.3 | 0.99 | 4.7 ± 2.1 | 1.09 | 268 ± 12.5 | 0.92 |
| 0.005 | 14.5 ± 3.4 | 0.74 | 84.7 ± 18.9 | 1.22 | 110.7 ± 10.5 | 1.07 | 6.3 ± 4 | 1.45 | 255.3 ± 26.5 | 0.88 | |
| 0.01 | 15.2 ± 6.2 | 0.77 | 89.3 ± 23 | 1.28 | 95.7 ± 15.6 | 0.92 | 2 ± 0 | 0.46 | 253 ± 46.5 | 0.87 | |
| 0.02 | 10.5 ± 2.3 | 0.53 | 71.7 ± 15.5 | 1.03 | 75.5 ± 30.4 | 0.73 | 4 ± 1.7 | 0.92 | 174.7 ± 15.6 | 0.60 | |
| 0.04 | 9.2 ± 2.5 | 0.47 | 72 ± 13.1 | 1.03 | 41.7 ± 4 | 0.40 | 1.3 ± 1.2 | 0.31 | 111.3 ± 9.1 | 0.38 | |
| PCd ( | 0.5 (4NQO) | 332 ± 22.6 | 20.68 | 464.3 ± 91.8 | 6.66 | — | — | — | — | 1031 ± 93.5 | 3.54 |
| 1 (NaN3) | — | — | — | — | 427.3 ± 31.2 | 4.12 | 312.3 ± 9 | 72.13 | — | — | |
|
| |||||||||||
| With metabolic activation (+S9) | |||||||||||
| NCc | — | 15.3 ± 1.5 | — | 100.7 ± 9.9 | — | 179.7 ± 11.1 | — | 9.3 ± 2.9 | — | 325.7 ± 15.5 | — |
| Essential oil | 0.005 | 19 ± 3.6 | 1.24 | 109.3 ± 8.5 | 1.09 | 155.7 ± 10 | 0.87 | 10.3 ± 4.5 | 1.1 | 310 ± 3.6 | 0.95 |
| 0.01 | 23.3 ± 1.5 | 1.52 | 112 ± 20.1 | 1.11 | 141.3 ± 12.6 | 0.79 | 8 ± 3 | 0.86 | 338 ± 12.7 | 1.04 | |
| 0.02 | 15.7 ± 1.5 | 1.01 | 115 ± 10.5 | 1.14 | 135.3 ± 6.7 | 0.75 | 7.7 ± 1.5 | 0.83 | 332.7 ± 29 | 1.02 | |
| 0.04 | 21 ± 9.5 | 1.37 | 113.7 ± 8.7 | 1.13 | 112 ± 14.9 | 0.62 | 8.3 ± 3.5 | 0.89 | 301.7 ± 26 | 0.93 | |
| 0.08 | 18.7 ± 1.2 | 1.22 | 131.7 ± 10.6 | 1.31 | 99.3 ± 14 | 0.55 | 7.7 ± 2.3 | 0.83 | 295.7 ± 31.1 | 0.91 | |
| PCe ( | 1 (AFB1) | 1587 ± 91.1 | 103.5 | 587 ± 88.5 | 5.83 | 660.7 ± 59.9 | 3.68 | — | — | — | — |
| 10 (2-AF) | — | — | — | — | — | — | 104.3 ± 12.1 | 11.18 | 767.3 ± 53.6 | 2.36 | |
aNumber of revertants/plate: mean of three independent experiments ± SD; bMI: mutagenic index (number of his+ induced in the sample/number of spontaneous his+ in the negative control). cNegative control: DMSO (10 µL) used as solvent for the extract. dPositive control (−S9): NaN3 (sodium azide) to TA100 and TA1535 and 4-NQO to TA97a, TA98, and TA102. ePositive control (+S9): AFB1 (aflatoxin B1) for TA97a, TA98, and TA100 and 2-aminofluorene for TA102 and TA1535; p < 0.01; p < 0.001, in relation to the negative control.
Replication index of cultures exposed for 3 h to Origanum majorana essential oil.
| Substance | Concentration | Replication factor (mean ± S.D.) | Replication index (%) |
|---|---|---|---|
| NCa | — | 0.809 ± 0.012 | 100 |
| Essential oil | 0.0005 | 0.823 ± 0.027 | 102 |
| 0.005 | 0.800 ± 0.035 | 99 | |
| 0.05 | 0.126 ± 0.028 | 15 | |
| 0.5 | 0 ± 0 | 0 | |
| 5 | 0 ± 0 | 0 |
aNegative control: DMSO (0.5%).
Replication index of cultures exposed to Origanum majorana essential oil for 3 h or 21 h.
| Substance | Concentration | 3 h | 21 h | ||
|---|---|---|---|---|---|
| Replication factor (mean ± S.D.) | Replication index (%) | Replication factor (mean ± S.D.) | Replication index (%) | ||
| NCa | — | 0.726 ± 0.021 | 100 | 0.820 ± 0.050 | 100 |
| Essential oil | 0.003125 | 0.735 ± 0.019 | 101 | 0.822 ± 0.036 | 100 |
| 0.00625 | 0.698 ± 0.021 | 96 | 0.809 ± 0.014 | 99 | |
| 0.0125 | 0.731 ± 0.012 | 101 | 0.837 ± 0.027 | 102 | |
| 0.025 | 0.722 ± 0.031 | 99 | 0.769 ± 0.024 | 94 | |
| Colchicineb | 0.75 | 0.501 ± 0.013 | 69 | — | — |
| Etoposideb | 0.25 | — | — | 0.767 ± 0.028 | 94 |
aNegative control: DMSO (0.5%). bPositive control.
Figure 1Micronucleus frequency of V79 cells exposed to different O. majorana essential oil (OMEO) concentrations for 3 h (white columns) and 21 h (black columns). Negative control: DMSO (0.5%); positive control: 0.75 μg/mL colchicine (3 h) and 0.25 μg/mL etoposide (21 h). p < 0.05; p < 0.01, in relation to the negative control (Student's t-test).